Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Hopewell Therapeutics is discovering, synthesizing, and developing the next generation of tissue-targeted lipid nanoparticles (ttLNPs) to bring genomic medicines to patients. They’re pursuing opportunities to redefine the non-viral delivery space for novel genomic medicines by designing systemically administered LNPs to specifically target extrahepatic tissues and cells throughout the body. Hopewell has built a robust intell...
Hopewell Therapeutics is discovering, synthesizing, and developing the next generation of tissue-targeted lipid nanoparticles (ttLNPs) to bring genomic medicines to patients. They’re pursuing opportunities to redefine the non-viral delivery space for novel genomic medicines by designing systemically administered LNPs to specifically target extrahepatic tissues and cells throughout the body. Hopewell has built a robust intellectual property portfolio with an expansive library of ionizable lipids and has established partnerships with several industry-leading companies.

List your booth number for exhibitions, ask us